CVE:DMA - DiaMedica Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$4.63 -0.10 (-2.11 %) (As of 02/20/2019 08:36 AM ET)Previous CloseC$4.73Today's RangeC$4.56 - C$4.9052-Week RangeC$3.33 - C$18.00Volume27,300 shsAverage Volume6,619 shsMarket CapitalizationC$36.38 millionP/E Ratio-5.91Dividend YieldN/ABetaN/A ProfileDiscussionChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Receive DMA News and Ratings via Email Sign-up to receive the latest news and ratings for DMA and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange CVE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolCVE:DMA Previous Symbol CUSIPN/A Webwww.diamedica.com Phone+1-763-4965454Debt Debt-to-Equity RatioN/A Current Ratio3.48 Quick Ratio3.37Price-To-Earnings Trailing P/E Ratio-5.91 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$503,657.00 Price / Sales72.23 Cash FlowC$0.50 per share Price / Cash Flow9.33 Book ValueC$0.17 per share Price / Book27.08Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees9 Outstanding Shares7,856,880Market CapC$36.38 million OptionableNot Optionable DiaMedica Therapeutics (CVE:DMA) Frequently Asked Questions What is DiaMedica Therapeutics' stock symbol? DiaMedica Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "DMA." When is DiaMedica Therapeutics' next earnings date? DiaMedica Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for DiaMedica Therapeutics. Has DiaMedica Therapeutics been receiving favorable news coverage? Media coverage about DMA stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. DiaMedica Therapeutics earned a news sentiment score of 1.4 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future. Who are some of DiaMedica Therapeutics' key competitors? Some companies that are related to DiaMedica Therapeutics include Aerpio Pharmaceuticals (ARPO), Pfenex (PFNX), Neuren Pharmaceuticals (NEU), Matinas Biopharma (MTNB), Equillium (EQ), Matinas BioPharma (MTNB), Covalon Technologies (COV), Immutep (IMM), Medicure (MPH), Acasti Pharma (ACST), Bionomics (BNO), IntelGenx Technologies (IGX), CEL-SCI (CVM), Orgenesis (ORGS) and Botanix Pharmaceuticals (BOT). Who are DiaMedica Therapeutics' key executives? DiaMedica Therapeutics' management team includes the folowing people: Mr. Rick Pauls M.B.A., MBA, Pres, CEO & Director (Age 48)Dr. Todd A. Verdoorn, Chief Scientific Officer (Age 58)Mr. Scott B. Kellen C.A., CFO & Company Sec. (Age 54)Mr. Edward B. Rady, Chief Commercial Advisor (Age 70)Dr. Dennis D. Kim M.D., MBA, Consulting Chief Medical Officer (Age 49) How do I buy shares of DiaMedica Therapeutics? Shares of DMA and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is DiaMedica Therapeutics' stock price today? One share of DMA stock can currently be purchased for approximately C$4.63. How big of a company is DiaMedica Therapeutics? DiaMedica Therapeutics has a market capitalization of C$36.38 million and generates C$503,657.00 in revenue each year. DiaMedica Therapeutics employs 9 workers across the globe. What is DiaMedica Therapeutics' official website? The official website for DiaMedica Therapeutics is http://www.diamedica.com/. How can I contact DiaMedica Therapeutics? DiaMedica Therapeutics' mailing address is 2 Carlson Pkwy N # N165, MINNEAPOLIS, MN 55447-4466, United States. The company can be reached via phone at +1-763-4965454. MarketBeat Community Rating for DiaMedica Therapeutics (CVE DMA)Community Ranking: 1.8 out of 5 ()Outperform Votes: 37 (Vote Outperform)Underperform Votes: 64 (Vote Underperform)Total Votes: 101MarketBeat's community ratings are surveys of what our community members think about DiaMedica Therapeutics and other stocks. Vote "Outperform" if you believe DMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DMA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/20/2019 by MarketBeat.com StaffFeatured Article: Is it better to buy a fund with a higher or lower NAV?